Brain tumors are the second most common childhood cancer. Treatment protocols for high-grade pediatric brain tumors recommend regular follow-up imaging for up to 10 years. We review maximal time to recurrence and minimal time to radiologically detectable long-term sequelae such as secondary malignancies, vascular complications, and white matter disease. No tumors recurred after the 10-year point, but radiological long-term sequelae grew more common as the treatment completion date receded. We do not recommend regular imaging more than 10 years after treatment has ended, unless there are clinical symptoms.
INTRODUCTION
Tumors of the central nervous system (CNS) are the second most common tumors in childhood after leukemia. The incidence is comparable in Western countries (5.47/100,000 aged 0-14 years and 5.67/100,000 aged 0-19 years in the United States, 2-4/100,000 aged 0-15 years in Germany and Switzerland). 1, 2 Advances in imaging techniques, neurosurgery, radiotherapy, chemotherapy, and supportive care have increased the survival rate significantly. Five-year relative survival for all brain tumors has increased from around 60% at the end of the 1970s to around 72.5% by 2007-2013, 3 though the survival rate varies between different pediatric CNS tumors. When they are cured of their primary malignancy, children need regular follow-up investigations and screenings for tumor recurrence and long-term side effects caused by chemotherapy, radiotherapy, surgery, or the tumor itself. For most tumors, a national and/or international treatment protocol recommends procedures for initial diagnosis, treatment, and follow-up, but these recommendations usually cover only the first 5 or 10 years after the end of treatment.
This review summarizes the most important findings detectable on imaging 10 years or more after the end of treatment for pediatric highAbbreviations: ATRT, atypical teratoid rhabdoid tumor; CNS, central nervous system; DIPG, diffuse intrinsic pons glioma; EPN, ependymoma; FA, fractional anisotropy; HGG, high-grade glioma; IVM, intracerebral vascular malformations; MB, medulloblastoma; MRI, magnetic resonance imaging; PNET, primitive neuroectodermal tumor; SMN, secondary malignant neoplasm; WML, white matter lesion grade brain tumors, which includes the period of possible tumor recurrence. We also summarize possible long-term sequelae visible on imaging (secondary malignant neoplasm [SMN] , vascular complications, and white matter disease) caused by the treatment.
METHODS
We used PubMed for the literature search. Search [DIPG] ) and the term "embryonal tumors". In addition to single biological subtypes, we combined those with the terms "surveillance imaging", "relapse", "relapse pattern", "outcome", "cavernoma", "intracerebral cavernous malformations", "intracerebral vascular malformations" (IVM), "secondary malignant neoplasm (SMN)", "secondary malignancy", "leukomalacia", "leukoencephalopathy", "white matter", and "childhood". We also screened reference lists of the eligible publications.
Inclusion criteria for all publications are diagnosis of a high-grade brain tumor and age at first tumor diagnosis of 0-18 years. We also included publications with patients aged >18 years if the proportion of the pediatric population was described separately. An additional inclu-sion criterion for tumor recurrence was diagnosis after 1999; these studies have comparable and less heterogeneous treatment modalities, especially for radiotherapy. We only evaluated time to first recurrence. SMN, IVM, and leukoencephalopathy have separate inclusion criteria for the year of first tumor diagnosis (after 1989) and year of publication (after 1999).
We excluded all publications with less than 10 patients and those where leukoencephalopathy developed during treatment. Patients with tumor predisposition syndrome are excluded, as in this population follow-up recommendations are more complex and have to include multiple different tumor types also outside of the CNS. Table 1 provides an overview of the most important findings from eligible studies on tumor recurrence.
RESULTS

Tumor recurrence
Medulloblastoma
MB makes up 15-30% of all brain tumors and is the second most common brain tumor after astrocytoma. 4 Around 50% develop before the age of 5 years. Initial metastatic disease is present in about one-third. 5, 6 Tumor recurrence rate was between 18.7-40%. 5, [7] [8] [9] [10] [11] [12] [13] [14] No relapse occurred more than 10 years after diagnosis. The longest documented latency period was 7.9 years in a patient with standard risk MB. 7 The proportion of late relapse, arbitrarily defined as >5 years from diagnosis, is mentioned in two publications and is 8% and 7%. 7 4, 15, 16 Thirty to 54% of patients relapsed between 1 month and 8.6 years from diagnosis, with a mean of 12-19 months. 9, [17] [18] [19] [20] No data concerning symptomatic or asymptomatic recurrence are available.
Atypical teratoid rhabdoid tumor
ATRT is a rare (1-2%) brain tumor in childhood and affects predominantly infants and toddlers. About two-thirds of newly diagnosed ATRT occur before the age of 3 years. In 21-30%, dissemination is present at initial diagnosis. [21] [22] [23] Relapse occurs in 40-74% of patients with a mean latency period of around 5 months and the latest relapse after 3.2 years. 9, [24] [25] [26] [27] [28] No data concerning symptomatic or asymptomatic recurrence are available.
CNS-PNET, pineoblastoma
CNS-PNET and pineoblastoma represent 2.5-4.8% and 0.6% of all CNS tumors, respectively. 4, 29 In the reviewed literature, initial metastatic disease was present in 35% and 48%, respectively. 10, 30 The rate of recurrence was between 42% and 76%. 10, 30, 31 The latest manifestation occurred after 4.5 years in a patient with CNS-PNET. 10 No data concerning symptomatic or asymptomatic recurrence are available.
HGG and DIPG
HGG, together with DIPG, represents 8-17% of all CNS tumors in childhood and adolescence up to 19 years of age and is responsible for a relevant part of mortality (up to 40% of all brain tumors). 4, 32, 33 According to data from four consecutive German HGG protocols, about 3% have initial metastatic disease. 34 The rate of progressive disease after 1 year was 75% in the study from Macy et al. 35 The event-free survival after 1 year was higher (43%) according to Wolff et al. 36 The 5-year event-free survival in this cohort was 13%. Table 2 summarizes the most important findings from eligible studies on SMN, IVM, and white matter lesion (WML).
Radiological long-term sequelae
Secondary malignant neoplasia
The median follow-up from diagnosis for the six eligible studies ranges 
Intracerebral vascular malformations
Only one study assessing radiation-induced cavernoma in patients with MB fulfilled the inclusion criteria. 41 During the observation period of mean 7.2 years, 31% developed at least one intracerebral cavernoma. The cumulative incidence rates 3, 5, and 10 years following radiotherapy for MB were 5.6%, 14%, and 43%, respectively. Time to detection of a vascular malformation lay between 1.1 and 16.1 years, with a median of 6.6 years. One out of 18 patients had clinical symptoms at diagnosis. He presented 5 years after treatment with seizure, headache, and emesis. All patients received radiotherapy to the brain.
Leukoencephalopathy/WML
WML is a well-known late effect after treatment for pediatric brain tumors, either after focal irradiation or after low-dose craniospinal n.a.
Abbreviations: CNS-PNET, central nervous system primitive neuroectodermal tumor; DIPG, diffuse intrinsic pons glioma; FU, follow-up; HGG, high-grade glioma; IMRT, intensity-modulated radiation therapy; PBL, pineoblastoma; PRT, proton-beam radiation therapy; SHH, sonic hedgehog. radiotherapy and chemotherapy. 42, 43 Depending on the severity, mostly studies classify WML in grade 1-3, rarely up to grade 4. Grade 1 lesions correspond to small areas with high signal in T2* and fluid attenuation inversion recovery in MRI. These lesions increase in grade 2 and become cystic or hemorrhagic in grade 3 and 4 lesions. 44 These changes can occur in parallel with an increase in subarachnoidal space and ventriculomegaly. 43 Different grades of WML can manifest in the same patient. [42] [43] [44] [45] The incidence of WML lies between 33% and 100%. [42] [43] [44] [45] [46] Two studies included MB only 42, 45, 46 ; the remaining two include more than one biological type of brain tumor. 43, 44 All patients received different combinations of chemotherapy and radiotherapy.
The percentage of grade 1 lesions in each study ranges from 33% to 66%. Grade II lesions and grade III lesions were visible in 7-33% and 29%, respectively.
DISCUSSION
We found no recurrence of the primary brain tumor, either local or distant, 10 years or more after the end of treatment in the reviewed Most of the SMN in the reviewed literature are high-grade tumors.
Only two studies reported occurrence of secondary meningioma. 37, 40 Studies with longer follow-up periods show a larger proportion of secondary meningioma. In the CCSS cohort, the cumulative incidence of benign meningioma was 3.3% after a median follow-up of 19.6 years. 51 The latency period for SMN in the brain is very TA B L E 2 Summary of the most important findings from eligible studies on secondary malignant neoplasm, intracerebral vascular malformation, and white matter lesion In case of absent neurological symptoms or deterioration, the management provides tight follow-up and surgery after delivery. The interval between diagnosis and surgery can thereby last up to several weeks. [52] [53] [54] To detect fast-growing secondary brain tumors (e.g., glioblastoma multiforme) at an early stage, the interval between scans would have to be very short; the possibility is high to miss the tumor on MRI because the tumor was not visible on the previous but manifests clinically before the subsequent examination. In summary, it is not possible to recommend regular screening for early detection of SMN.
Study/Year
Cavernomas occur more often in previously irradiated patients and detection rate depends on imaging techniques. The prevalence of cavernoma in the reviewed study is 31%. This prevalence is higher than that in nonirradiated children and young adults, with a prevalence of 0.6%, 55 and also higher than that in other publications including patients partially diagnosed before 1990 with rates of 3.4% and 4.2%. 56, 57 Different MRI techniques could cause some of these differences. In the study from Burn et al., no T2*-weighted imaging was performed. 56 This technique is sensitive to detect blood artefacts and was used in the reviewed study. Studies including patients from past eras, not using specific MR techniques, probably underestimate the prevalence of cavernoma. Cavernomas bear the risk of spontaneous bleeding. In the study from Lew et al., 20 lesions were longitudinally followed. 41 They increased in size in 70% of cases, were stable in 15%, and decreased in 15%. Despite an increase in size in 70% of cases, no patient suffered from acute bleeding during the follow-up period. The hemorrhage rate in nonirradiated children is 3.3% and 1.6% per patient year. 55, 58 Other publications show a bleeding rate for radiation-induced cavernoma of 10%. 59 Radiation dose and time of follow-up may have an effect on the development of cavernoma. Unfortunately, the reviewed study did not comment on the possible effect of radiation dose. Cutsforth et al. showed that patients treated with higher radiation doses had a shorter period to detection of cavernoma. 59 Burn et al. showed no correlation between radiation dose and latency period. 56 According to Lew et al., with increasing time from end of treatment, the cumulative incidence of cavernoma increases. 41 With the knowledge of the dynamic behavior in the natural course of cavernoma, we recommend a wait-andsee strategy with close follow-up imaging in case of an asymptomatic incidental finding. Due to the wide range of latency period to detection of cavernoma, no interval for regular follow-up imaging can be deduced.
A second cerebral vascular disorder observed after radiotherapy to the brain is moyamoya. Most studies evaluating moyamoya after radiotherapy include, to a large proportion, patients with neurofibromatosis 1 (NF1), a tumor predisposition syndrome. These patients are at increased risk for moyamoya independent of radiotherapy and separate guidelines for surveillance imaging exist. After excluding these patients from otherwise eligible studies, the number of patients without moyamoya is far less than 10. 60, 61 Both studies showed that radiation to the circle of Willisi or the supratentorial region is a risk factor for moyamoya. In the study from Ullrich et al. 60 , the high rate of optic pathway glioma and therefore patients probably having NF1 might bias this observation. In the population of Wu et al. 61 , only 25% suffered from optic pathway glioma, but all received suprasellar radiotherapy. Therefore, suprasellar radiotherapy seems to be a risk factor for moyamoya.
Most WML in the reviewed literature are grade 1. In the cohort from Dietrich et al. 44 , no child with WML suffered from neurological deficits, but specific neuropsychological testing was not performed. In three studies, imaging by conventional MRI was completed by the measurement of white matter anisotropy, performed by fractional anisotropy (FA). 42, 45, 46 Results show a relevant reduction of FA in selected parts of the brain in previously irradiated children compared to nonirradiated brains. There seems to be a correlation between FA reduction and younger age at radiotherapy as well as a time span of more than 5 years after radiation. A reduced FA or white matter integrity shows a correlation with lower cognitive outcome and executive functions. 42, 46 It seems that special imaging modalities (e.g., diffusion weighted imaging, measurement of anisotropy) are more sensitive in detection of WML than T2 weighted images alone. 42 The consequences of detected WML of any grade and the implications for therapeutic interventions are the focus of current research. We assume that early intervention, already preventive, with specific neuropsychological training may help these patients prevent the development or progression of impaired cognitive and executive functions.
The small number of studies that were eligible after we applied strict inclusion criteria, especially the limits imposed by year of diagnosis and the requirement for at least 10 patients, limited our review.
Since diagnoses were from 1990 onwards, the follow-up period was short, which probably biases the distribution towards more highgrade SMN and underestimates the rate of low-grade SMN. The large differences in cumulative incidence rates of vascular malformations we identified are most likely a result of small sample sizes and imaging techniques. Patients have been treated with newer modalities; therefore, our results apply to survivors now entering follow-up care.
If a patient has a strong new headache or neurological symptoms 10 years or more after treatment for a high-grade brain tumor, we recommend prompt imaging, including appropriate sequences for vascular diseases. If imaging reveals cavernoma in a critical region, we recommend regular follow-up imaging. 62 We do not recommend surveillance imaging for small cavernoma in noncritical regions. 41 We found that screening imaging more than 10 years after completing treatment for childhood high-grade brain tumors is not indicated in the absence of clinical symptoms because tumors do not recur after such a long period of time, and long-term sequelae (SMN, IVM, WML) occur in such a broad time spectrum that no reasonable interval for screening imaging can be defined.
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